Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narrative review, we have assessed the clinical development of CFZ, starting from the potential mechanism of actions, to the spectrum of side effects and potential drug-drug interactions, highlighting its current place in therapy and future possible use in leprosy, nontuberculous mycobacterial diseases and drug-resistant tuberculosis.

Download full-text PDF

Source
http://dx.doi.org/10.2217/fmb-2019-0231DOI Listing

Publication Analysis

Top Keywords

leprosy nontuberculous
8
nontuberculous mycobacterial
8
mycobacterial diseases
8
side effects
8
clofazimine drug
4
drug never-ending
4
never-ending diseases
4
diseases clofazimine
4
clofazimine cfz
4
cfz hydrophobic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!